In Parkinson's disease (PD) patients, alpha-synuclein (α-syn) pathology advances in form of Lewy bodies and Lewy neurites throughout the brain. Clinically, PD is defined by motor symptoms that are predominantly attributed to the dopaminergic cell loss in the substantia nigra. However, motor deficits are frequently preceded by smell deficiency or neuropsychological symptoms, including increased anxiety and cognitive dysfunction. Accumulating evidence indicates that aggregation of α-syn impairs synaptic function and neurogenic capacity that may be associated with deficits in memory, learning and mood. Whether and how α-syn accumulation contributes to neuropathological events defining these earliest signs of PD is presently poorly understood. We used a tetracycline-suppressive (tet-off) transgenic mouse model that restricts overexpression of human A30P α-syn to neurons owing to usage of the neuron-specific CaMKIIα promoter. Abnormal accumulation of A30P correlated with a decreased survival of newly generated neurons in the hippocampus and olfactory bulb. Furthermore, when A30P α-syn expression was suppressed, we observed reduction of the human protein in neuronal soma. However, residual dox resistant A30P α-syn was detected in glial cells within the hippocampal neurogenic niche, concomitant with the failure to fully restore hippocampal neurogenesis. This finding is indicative to a potential spread of pathology from neuron to glia. In addition, mice expressing A30P α-syn show increased anxiety-related behavior that was reversed after dox treatment. This implies that glial A30P α-synucleinopathy within the dentate gyrus is part of a process leading to impaired hippocampal neuroplasticity, which is, however, not a sole critical event for circuits implicated in anxiety-related behavior.
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Introduction
In Parkinson's disease (PD), the natively unfolded protein alphasynuclein (α-syn) aggregates into Lewy bodies (LB) and Lewy neurites (LN) through the transition from monomers into stable fibrils via intermediate oligomers (Conway et al., 2000b) . Differences in fibrillization rate have been observed in relation to distinct mutations within the α-syn gene. In particular the A30P mutation appears to promote its conversion into oligomers (Conway et al., 1998; Li et al., 2002; Narhi et al., 1999) whilst exhibiting a slow propensity to fibrillize (Choi et al., 2004; Conway et al., 2000a; Li et al., 2001) . Additionally, increased levels derived from impaired clearance of the protein by lysosome and/or the proteasome (Cuervo et al., 2004; Nonaka and Hasegawa, 2009 ) may incite both release (Jang et al., 2010; Lee et al., 2005) and seeding effects of neurotoxic α-syn species on its soluble counterpart; thus starting a vicious cycle of further α-syn conversion, overload of protein degradation systems and exocytosis that may hasten cell death. These neurodegenerative processes are typically accompanied by reactive gliosis. Contributing glial cells overexpress GFAP to form stable astrocytic processes and S100B, a neurotrophic factor that is known to stabilize calcium homeostasis and to balance oxidative stress (Rothermundt et al., 2003) . The topographical pattern of the neurotoxic progression suggests a spread of α-synucleinopathy within regions of the central nervous system, probably through cell-to-cell transfer between neurons (Desplats et al., 2009) or neuron to glia (Lee et al., 2010a) . Despite the detection of this pattern the underlying mechanisms of disease progression that contribute to earliest PD symptoms as smell deficit, anxiety, Neurobiology of Disease 59 (2013) 38-51 
